GLP-1 medications are the most cost-impactful new drug class in two decades. Insurance plans have responded with a patchwork of coverage rules — varying by employer, plan tier, indication, and state. Understanding the landscape before you start prevents months of denied claims and unexpected pharmacy bills.
Coverage by indication
Type 2 diabetes: most commercial plans cover Ozempic, Trulicity, Mounjaro at standard formulary tier with prior authorization. Coverage is generally straightforward when an A1c ≥6.5% is documented.
Weight loss (Wegovy, Zepbound): coverage is much narrower. About 30–40% of commercial plans covered Wegovy in 2025, often with restrictive criteria — BMI ≥30 or ≥27 with comorbidities, documented prior weight loss attempts, sometimes a 6-month observation period. Prior authorization is essentially universal. Some self-funded employer plans explicitly exclude weight-loss medications.
Cardiovascular indication: Wegovy received an FDA indication for cardiovascular risk reduction in 2024, which expanded coverage in some plans. Coverage rules are evolving rapidly.
Medicare landscape
Medicare Part D historically did not cover weight-loss medications by statute. The Inflation Reduction Act and subsequent CMS guidance opened new pathways in 2024–2025; coverage rules are evolving. Ozempic for diabetes is covered. Wegovy specifically for cardiovascular risk reduction in patients with established cardiovascular disease has been added at some plan levels. Pure weight-loss Wegovy/Zepbound coverage in Medicare remains limited as of mid-2026.
Medicaid landscape
Medicaid coverage varies dramatically by state. About 14 state Medicaid programs cover GLP-1 for weight loss as of 2026; the others cover only for diabetes. Check your specific state — the picture changes annually.
Navigating prior authorization
Most PAs for GLP-1 require: documented BMI (current and historic), documented weight-loss attempts (lifestyle program enrollment is often counted), documentation of obesity-related comorbidities (hypertension, dyslipidemia, sleep apnea, T2D, NAFLD), and the clinician's direct prescription justification. Prepare your clinician's office to submit these — many denials are due to missing documentation rather than coverage exclusion.
When PA is denied — the appeal process
First-level appeal: typically a re-review by the insurer's medical director. About 30–40% succeed. Second-level appeal: independent medical review by an external party. About 50% of escalated appeals succeed. Appeal letters should include: documented BMI history, comorbidities, prior treatment failures, and any cardiovascular indication if applicable.
Cash and compounded paths
When insurance won't cover, the practical alternatives are cash-pay branded (often $1,000–1,350/mo for Wegovy/Zepbound, sometimes reduced with manufacturer savings cards to $200–500/mo for the first months) or compounded GLP-1 ($200–400/mo). Manufacturer savings cards are time-limited and often have income cutoffs.
HSA / FSA eligibility
GLP-1 medications prescribed for treatment of a diagnosed medical condition (obesity, diabetes, cardiovascular risk) are HSA/FSA eligible. Many plans require a Letter of Medical Necessity. GLP-1 prescribed for cosmetic weight loss is not eligible.
Practical checklist before you start
Call your insurance member services — ask: Is Wegovy/Zepbound on formulary? At what tier? What are the prior auth criteria? Is there a step-therapy requirement? Is there a quantity limit? What's the copay at each fill? Get the answers in writing or save the call reference. This 15-minute call prevents the most common cost surprises.
Informational only — coverage rules change frequently. Verify current status with your insurer and clinician.